StockData

Meihua International Medical Technologies Co., Ltd. (MHUAF) stock analysis

MHUAFOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 5/30
$6.50+0.00 (0.00%)

Close on Oct 19, 2026Market cap –P/E 0.4Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value0Growth0Performance2Health3Dividend0

Weak5 of 30 checks passed

Meihua International Medical Technologies passes 5 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
0/6
Past performance
2/6
Financial health
3/6
Dividend
0/6

What stands out

  • Low debt

    Debt is 4.8% of shareholders' equity, under the 40% we consider low.

  • Interest well covered

    Operating income covers interest expense 34.3 times.

  • Return on equity above the industry

    Meihua International Medical Technologies's return on equity of 3.9% is above the Surgical, Medical, and Dental Instruments and Supplies median of -30.1%.

  • Net margin above the industry

    Meihua International Medical Technologies's net margin of 11.0% is above the Surgical, Medical, and Dental Instruments and Supplies median of -12.9%.

What to watch

  • Return on equity under 15%

    Return on equity was 3.9% over the last twelve months and averaged 9.2% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 3.6%, below the 10% that usually covers the cost of capital.

  • Earnings shrank over 5 years

    Net income shrank 18.7% a year on average over the last five fiscal years.

  • Revenue growing under 10% a year

    Revenue grew -15.8% a year over the last three fiscal years, short of the 10% we look for.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth0/6

  • Revenue growing under 10% a year

    Revenue grew -15.8% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -12.6% a year over the last three fiscal years.

  • Earnings growth not accelerating

    Net income grew -37.5% over the last twelve months, against a 5-year average of -18.7% a year.

  • Growing slower than the industry

    Revenue grew -36.2% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 10.6%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 31.0% over the last twelve months, against 34.4% a year earlier.

Past performance2/6

  • Return on equity under 15%

    Return on equity was 3.9% over the last twelve months and averaged 9.2% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 3.6%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Meihua International Medical Technologies's return on equity of 3.9% is above the Surgical, Medical, and Dental Instruments and Supplies median of -30.1%.

  • Earnings shrank over 5 years

    Net income shrank 18.7% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was 11.0% over the last twelve months, against a 5-year average of 12.1%.

  • Net margin above the industry

    Meihua International Medical Technologies's net margin of 11.0% is above the Surgical, Medical, and Dental Instruments and Supplies median of -12.9%.

Financial health3/6

  • Low debt

    Debt is 4.8% of shareholders' equity, under the 40% we consider low.

  • Debt rising against equity

    Debt to equity rose from 3.8% five years ago to 4.8%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 6.3% of total debt; we look for at least 20%.

  • Interest well covered

    Operating income covers interest expense 34.3 times.

  • Short-term assets cover short-term debts

    Current assets are 8.42 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Meihua International Medical Technologies has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Meihua International Medical Technologies. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2018 to 2025

Gross margin

31.0%−10.7 pts over 5 years

Operating margin

13.4%−12.9 pts over 5 years

Net margin

11.0%−10.4 pts over 5 years

See a number that looks wrong?